Intervention Review

You have free access to this content

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer

  1. Theresa A Lawrie1,
  2. Andrew Bryant2,
  3. Alison Cameron3,*,
  4. Emma Gray4,
  5. Jo Morrison5

Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

Published Online: 9 JUL 2013

Assessed as up-to-date: 2 JUL 2013

DOI: 10.1002/14651858.CD006910.pub2


How to Cite

Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD006910. DOI: 10.1002/14651858.CD006910.pub2.

Author Information

  1. 1

    Royal United Hospital, Cochrane Gynaecological Cancer Group, Bath, UK

  2. 2

    Newcastle University, Institute of Health & Society, Newcastle upon Tyne, UK

  3. 3

    University Hospitals Bristol NHS Foundation Trust, Department of Clinical Oncology, Bristol, UK

  4. 4

    Musgrove Park Hospital, The Beacon Centre, Taunton, Somerset, UK

  5. 5

    Musgrove Park Hospital, Department of Obstetrics and Gynaecology, Taunton, Somerset, UK

*Alison Cameron, Department of Clinical Oncology, University Hospitals Bristol NHS Foundation Trust, Bristol Haematology and Oncology Centre, Horfield Road, Bristol, BS2 8ED, UK. Alison.Cameron@UHBristol.nhs.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 9 JUL 2013

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sina Eetezadi, Raquel De Souza, Mirugashini Vythilingam, Rodrigo Lessa Cataldi, Christine Allen, Effects of Doxorubicin Delivery Systems and Mild Hyperthermia on Tissue Penetration in 3D Cell Culture Models of Ovarian Cancer Residual Disease, Molecular Pharmaceutics, 2015, 12, 11, 3973

    CrossRef